BiotechTube
ConSynance Therapeutics

ConSynance Therapeutics

Cambridge, United States· Est.
consynance.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

ConSynance Therapeutics, founded in 2021 and based in Cambridge, USA, is a private, clinical-stage biotech focused on rare CNS diseases. Its lead asset, CSTI-500, is a Phase 2-ready, tunable triple monoamine reuptake inhibitor aimed at treating hyperphagia and behavioral dysregulation in Prader-Willi Syndrome. The company is led by a lean, experienced team with deep expertise in CNS drug development, chemistry, and regulatory affairs, positioning it to advance its novel mechanism into critical proof-of-concept studies.

Rare CNS DiseasesNeuropsychiatryNeurodevelopmental Disorders

Technology Platform

Tunable triple monoamine reuptake inhibitor (TRI) platform designed to simultaneously modulate serotonin, dopamine, and norepinephrine levels with adjustable selectivity.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The primary opportunity is addressing the catastrophic unmet need for hyperphagia treatment in Prader-Willi Syndrome, a rare disease with no approved pharmacotherapy, allowing for premium pricing and orphan drug incentives.
Success in PWS would validate the tunable TRI platform, enabling expansion into other rare CNS disorders with similar dysregulation of monoamine pathways.

Risk Factors

Key risks include clinical failure of CSTI-500 in Phase 2 trials, given the unproven efficacy of the mechanism in PWS, and financial risk associated with raising sufficient capital to fund expensive late-stage development.
The company also faces competitive and regulatory risks from other developers and evolving endpoints for hyperphagia trials.

Competitive Landscape

The competitive landscape for Prader-Willi Syndrome hyperphagia is emerging but lacks an approved drug. Competitors include companies developing oxytocin analogs, GLP-1 agonists, and other neurotransmitter modulators. ConSynance's differentiation lies in its novel, tunable triple mechanism aiming to address both hyperphagia and core behavioral symptoms simultaneously.

More companies in Small Molecule Drugs →More companies in United States →